Please login to the form below

Not currently logged in
Email:
Password:

FDA accepts Wyeth's Tygacil sNDA for review

US-based Wyeth Pharmaceuticals has reported that the FDA accepted its supplemental new drug application (sNDA) for first-in-class antibiotic Tygacil (tigecycline) for the treatment of patients with community-acquired pneumonia.

US-based Wyeth Pharmaceuticals has reported that the FDA accepted its supplemental new drug application (sNDA) for first-in-class antibiotic Tygacil (tigecycline) for the treatment of patients with community-acquired pneumonia.

The agency will complete its review of the application and may approve or disapprove the application, request additional data or take other administrative actions.

The sNDA submission included integrated data from two investigational clinical studies involving 846 patients. Study data showed that Tygacil cured 89.7 per cent of patients hospitalised with community-acquired pneumonia (CAP), and levofloxacin, an existing treatment option for CAP, cured 86.3 per cent of studied patients.

The most common adverse events for Tygacil were nausea, vomiting and abdominal pain. The discontinuation rates due to adverse events for Tygacil and levofloxacin were similar, 6.1 per cent and 8.3 per cent, respectively.

The FDA approved Tygacil in June 2005 for use in hospital patients with serious bacterial infections, including those
resistant to most other antibiotics. The intravenous drug is used as a first-line treatment for stomach and skin infections and is effective against enough different bacteria to be used before doctors know which ones are causing the infection.

Gary Stiles, Wyeth's CMO, said: "Community-acquired pneumonia is a serious respiratory disease that affects millions of Americans. The acceptance of this sNDA is an important event as it brings Wyeth closer to providing physicians with a new option for the treatment of CAP."

For Q3 FY07, Wyeth said that Tygacil hit the USD 100m mark and added that it was on track to meet its goal of doubling FY06 revenues, driven by US growth.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics